Warning: include(html/com_content/archive/function.php): failed to open stream: No such file or directory in /home/content/50/3396850/html/templates/driverally/index.php on line 66

Warning: include(): Failed opening 'html/com_content/archive/function.php' for inclusion (include_path='.:/usr/local/php5_4/lib/php') in /home/content/50/3396850/html/templates/driverally/index.php on line 66

Good Manufacturing Practice Requirements for Combination Products

Earlier this week the FDA released its Final Rules regarding Good Manufacturing Practice Requirements for Combination Products.  The Food and Drug Administration (FDA or Agency) is issuing this regulation on the current good manufacturing practice (CGMP) requirements applicable to combination products. This rule is intended to promote the public health by clarifying which CGMP requirements apply when drugs, devices, and biological products are combined to create combination products. In addition, the rule sets forth a transparent and streamlined regulatory framework for firms to use when demonstrating compliance with CGMP requirements for “single-entity” and “co-packaged” combination products.

Products Affected Include

  1. Existing Combination Products
    • The FDA will provide help for manufacturers to alter systems as need be for existing products
  2. New Combination Products
  3. Component manufacturers are exempt from the CGMP rules even if a component will be incorporated into the final product.

More Information

Combination Product Definition

Combination products are defined in 21 CFR 3.2(e).  The term combination product includes:

  1. A product comprised of two or more regulated components, i.e., drug/device, biologic/device, drug/biologic, or drug/device/biologic, that are physically, chemically, or otherwise combined or mixed and produced as a single entity;
  2. Two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products;
  3. A drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or
  4. Any investigational drug, device, or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect.
Thursday the 20th. Copyright © 2008-2016 Knowvention, LLC All Rights Reserved - Templates Joomla